Vitiligo: The Association With Metabolic Syndrome and the Role of Simvastatin as an Immunomodulator.

dyslipidemia hypertension metabolic syndrome obesity simvastatin vitiligo

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
22 Mar 2021
Historique:
entrez: 26 4 2021
pubmed: 27 4 2021
medline: 27 4 2021
Statut: epublish

Résumé

Vitiligo is an autoimmune condition primarily affecting the skin where there is destruction of melanocytes characterized by pinkish-white patches on the skin. It is associated with other autoimmune diseases such as thyroid disease, rheumatoid arthritis, diabetes mellitus, and metabolic syndrome. Metabolic syndrome is a constellation of disorders including insulin resistance, hypertension, dyslipidemia, and obesity, and is considered a leading cause of cardiovascular morbidity. Simvastatin is a potent hypolipidemic drug that also possesses immunomodulating properties and is a common drug used in dyslipidemia and cardiovascular diseases. This study aimed to assess the association between vitiligo and metabolic syndrome and explore the immunomodulating properties of simvastatin for use in vitiligo. We reviewed various articles from PubMed, ResearchGate, and Google Scholar using different keywords and Medical Subject Headings and finalized 33 studies to be used in our review. The articles selected showed a positive association between vitiligo and metabolic syndrome or one of the component diseases of metabolic syndrome. The benefits of using simvastatin were also addressed by few articles attributing to its antioxidant and immunomodulating effect. However, there was no concrete explanation justifying the association between vitiligo and metabolic syndrome due to a limited number of studies and smaller sample size. Large-scale clinical trials should be conducted to evaluate the use of simvastatin as an immunomodulator in vitiligo to prevent possible metabolic complications.

Identifiants

pubmed: 33898117
doi: 10.7759/cureus.14029
pmc: PMC8059484
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

e14029

Informations de copyright

Copyright © 2021, Verma et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Am Acad Dermatol. 2017 Jan;76(1):150-151.e3
pubmed: 27986135
Acta Derm Venereol. 2011 Sep;91(5):541-4
pubmed: 21597678
Int J Dermatol. 2014 Aug;53(8):956-8
pubmed: 24134629
An Bras Dermatol. 2020 Mar - Apr;95(2):165-172
pubmed: 32113676
Front Endocrinol (Lausanne). 2019 Jan 15;9:803
pubmed: 30697190
Trials. 2019 Jan 25;20(1):78
pubmed: 30683146
Dermatology. 1994;189(4):350-3
pubmed: 7873818
Indian J Dermatol. 2017 Mar-Apr;62(2):168-170
pubmed: 28400636
J Am Acad Dermatol. 2019 Dec;81(6):1442-1445
pubmed: 31228523
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Pigment Cell Melanoma Res. 2021 May;34(3):598-604
pubmed: 33098225
Clin Cosmet Investig Dermatol. 2020 Jun 22;13:425-430
pubmed: 32606881
Acta Dermatovenerol Croat. 2014;22(1):19-25
pubmed: 24813837
Balkan Med J. 2017 May 5;34(3):219-225
pubmed: 28443562
J Clin Lab Anal. 2011;25(2):110-2
pubmed: 21438003
Clin Lab. 2020 Oct 1;66(10):
pubmed: 33073941
Lipids Health Dis. 2004 May 10;3:7
pubmed: 15134579
J Clin Aesthet Dermatol. 2019 Nov;12(11):28-31
pubmed: 32038754
Biochim Biophys Acta Mol Basis Dis. 2017 May;1863(5):1066-1077
pubmed: 27836629
Indian Dermatol Online J. 2014 Oct;5(4):456-60
pubmed: 25396128
J Invest Dermatol. 2017 Jun;137(6):1286-1296
pubmed: 28174051
Endocr Rev. 2019 Jun 1;40(3):789-824
pubmed: 30649221
Pigment Cell Res. 2000 Feb;13(1):28-32
pubmed: 10761993
Free Radic Res. 2017 Dec;51(11-12):986-994
pubmed: 29182456
Saudi Med J. 2017 Apr;38(4):400-404
pubmed: 28397947
Clin Exp Dermatol. 2004 Jul;29(4):406-9
pubmed: 15245542
J Investig Med. 2021 Feb;69(2):393-396
pubmed: 33093072
Exp Dermatol. 2004 Jun;13(6):337-9
pubmed: 15186318
Arch Dermatol Res. 2009 Oct;301(10):731-7
pubmed: 19488773
J Am Acad Dermatol. 2019 Mar;80(3):646-654.e5
pubmed: 30165163
Diabetes Metab Syndr. 2017 Nov;11 Suppl 1:S77-S80
pubmed: 28017282
Diabetes. 2003 May;52(5):1210-4
pubmed: 12716754

Auteurs

Deepak Verma (D)

Internal Medicine/Family Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.

Khadija Hussain (K)

Radiology, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.

Karez S Namiq (KS)

Oncology, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.

Amena Firoz (A)

Pediatrics, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.

Manel Bouchama (M)

Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.

Maham Raza (M)

Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.

Muhammad Haris (M)

Internal Medicine, Royal Lancaster Infirmary, Lancaster, GBR.
Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.

Safeera Khan (S)

Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.

Classifications MeSH